Fetal @entity934 receptor inactivation syndrome: XXXX due to maternal antibodies.

@entity1 @entity4653 @entity27939 @entity455 @entity8482 @entity1739 @entity1737 @entity2203 @entity393 @entity121 @entity934
BACKGROUND: @entity27939 ( @entity27939 ) affects a proportion of @entity1 born to mothers with @entity1737 ( @entity1737 ). Symptoms usually resolve completely within the first few months of life, but persistent @entity121 have been reported in a few isolated cases. METHODS: Here we report 8 @entity1 from 4 families born to mothers with clinically manifest @entity1737 or mothers who were asymptomatic but had elevated @entity934 receptor (AChR) antibody levels. RESULTS: Clinical features in affected @entity1 ranged from a mild predominantly facial and bulbar @entity121 to @entity8482 . Additional clinical findings included @entity393 , @entity2203 , and mild CNS involvement. In all cases, antibodies against the AChR were markedly elevated, although not always specific for the fetal AChR y subunit. There was a correlation between maternal symptoms; the timing, intensity, and frequency of maternal treatment; and neonatal outcome. CONCLUSIONS: These findings suggest that persistent @entity121 following @entity27939 may be more common than currently recognized. Fetal AChR inactivation syndrome should be considered in the differential diagnosis of @entity1 presenting with unexplained @entity121 , in particular marked @entity4653 and @entity1739 . Correct diagnosis requires a high degree of suspicion if the mother is asymptomatic but is crucial considering the high recurrence risk for future pregnancies and the potentially treatable nature of this condition. @entity1 with a history of @entity27939 should be followed up for @entity455 .
